AI assistant
Korro Bio, Inc. — Director's Dealing 2023
Aug 14, 2023
33032_dirs_2023-08-14_9313c3be-126e-4537-8366-640fff5e2044.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Frequency Therapeutics, Inc. (FREQ)
CIK: 0001703647
Period of Report: 2023-08-10
Reporting Person: Mitrano Richard J. (VP Finance & Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-10 | Common Stock | S | 247 | $.64 | Disposed | 50091 | Direct |
| 2023-08-11 | Common Stock | S | 240 | $.64 | Disposed | 49851 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4032 | Indirect |
Footnotes
F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.642 to $0.661. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.636 to $0.641. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.